Taken together, these data suggest that GLP-1 receptor agonists such as exenatide and AC3174 have potential as therapeutic agents for preventing and attenuating the development of hypertension and cardiac hypertrophy. This evidence concerns the gene GLP1R and hypertensive disorder.